PHOTONICS | ARTICLE << Figure 5 >>


Lowering the power of the laser directly increases the noise as they no longer operate at their preferred operation point. The VOA for visible wavelengths offers the possibility to run a laser at its preferred output state and the power can be adjusted to match the level of the specific measurements.


The VOA function can also be combined with the combiner or splitter functions, which creates an adjustable combiner or splitter. With such type of function combinations, the true advantages of using PICs become apparent (figure 5).


Fringe pattern generator An application demonstrating how PICs can be used in cooperation with freespace optics, a fringe pattern generator is developed. As the phase of the light can be controlled very accurately on the visible PIC, fringe patterns can be made and controlled that are projected on a surface. The example in figure 6 shows the principle of a simple two channel version. But the principle can be extended to more channels, allowing even more flexibility in the number of fringes and the fringe shape and pattern.


Conclusion PIC technology for visible light can enable new applications which are not possible to realise with existing discrete components. We have shown several examples from our library of passive and active optical functions such as wavelength combiners, power splitters, switches, filter components, variable attenuators and modulators. Several application examples have been shown to demonstrate the creation of new functionalities by combining more on-chip function to one.


XiO Photonics www.xiophotonics.com


<< Figure 6 >>


http://www.mancef.org


Next-Gen Pharmaceutical Industry Landscape


Presented by MANCEF and contributed to by professionals around the world…Emerging Technology road mapping has evolved once again. The pharmaceutical industry—like most other industries—is being redefined by exceptional changes in its manufacturing processes.Pharma has switched from a single root multiple technology based solutions.


technology based solution to


Today, pharmaceutical solutions are not simply based on a single chemical isomer but are much more often based on multiple technologies from the following technology set: Nanotechnology, MEMS, Biological solutions such as tissue engineering, more complex chemistries, and computational sciences. Yet how can a firm,


region, government


policymaker, educator, or investor make decisions about the future? Market, technical, and social drivers are much more important in today’s pharmaceutical landscape. The answer is a deeper understanding of the newest road mapping process: Landscaping. 


Modern pharmaceutical solutions rely on advances in at least five technological pathways. Simple, traditional semiconductor-like road mapping practices (where the assumption of a unit product and a single technological pathway with a single technology trajectory) simply cannot assist in developing this new pharmaceutical system. It takes a 3rd generation model to develop a meaningful road mapping process: one that is focused on drivers. Here we identify 18 technological, market, regulatory, and manufacturing drivers. The new model must also account for the industry’s new structure, and our new road map describes the advent of consortia (now well over 100, when in 1990 there were less than five).  This Landscape has over 350 pages and describes in detail all drivers, technology subcomponents, and a process for you to develop your own internal roadmap. We identify 80+ consortia, as well as numerous firms involved in the industry.


Only USD 250 For more details please contact Rob Haak at rhaak@mancef.org 42 | commercial micro manufacturing international Vol 7 No.4


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52